References in periodicals archive ?
The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Other innovative projects currently in development include SEL141, an early stage discovery program of DYRK1A kinase inhibitors with therapeutic potential in the treatment targeting Alzheimer's disease and Down syndrome, SEL201-novel small molecule MNK1/2 inhibitors in oncology, cancer metabolism platform and inflammasome platform.
These changes included NRAS [neuroblastoma RAS viral (v-ras) oncogene homolog] and CDK8 (cyclin-dependent kinase 8) aberrations that were labeled as "informative" because they could be matched in the future to clinical trials with MEK, PI3K, or CDK inhibitors.
When further investigating macroH2A function in melanoma, the researchers found that it regulates CDK8, a known oncogene for colorectal cancer.
Scientists think the gene CDK8 plays a role in many varieties of colon cancer.
The gene - called CDK8 - was found to be prevalent among colon cancer victims after scientists scanned tumour cells for genes that drive the spread of colon cancer cells and therefore tumours.
Cancer therapies company Selvita (WSE:SLV) stated on Tuesday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to launch Phase 1 study of selective CDK8 inhibitor SEL120 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS).
Acronyms browser ?
Full browser ?
- CDK2-associated dual specificity phosphatase
- CDK2-associated dual-specificity phosphatase
- CDK4 gene
- CDK4 gene
- CDK4 inhibitor p16-INK4, INK4a
- CDK4B inhibitor
- CDK5-Binding Protein
- CDK6 inhibitor p18
- CDK8 protein kinase
- CDK8-like cyclin-dependent kinase
- CDK9-associated C-type protein